GPER1 and cancer: Taking also into account that one in four patients with ER-positive tumors does not respond to anti-estrogens (16), the existence of an alternative estrogen receptor as GPER, may provide the basis for a better understanding of novel mechanisms by which estrogens/anti-estrogens stimulate the proliferation of hormone-sensitive cancer cells, including breast carcinoma.